GRPR and cancer: However, the current clinically validated GRPR-targeted radioligands show an extremely high uptake in pancreas (Baum et al. 2007; Kähkönen et al. 2013; Kurth et al. 2020; Nock et al. 2017; Minamimoto et al. 2016), which not only limits the detection of cancer lesions located in or adjacent to pancreas, but also lowers the maximum tolerated dose for targeted radioligand therapy.